ClinicalTrials.gov record

Completed Not applicable Interventional Accepts healthy volunteers Results available

Varenicline for the Treatment of Smokeless Tobacco

ClinicalTrials.gov ID: NCT00813917

Public ClinicalTrials.gov record NCT00813917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Varenicline for the Treatment of Smokeless Tobacco Use

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Varenicline (Chantix™, Pfizer) is a novel selective nicotinic receptor partial agonist with specificity for the α4β2 nicotine acetylcholine receptor that has demonstrated remarkable efficacy for increasing long-term tobacco abstinence rates in cigarette smokers. The novel mechanism of action of varenicline potentially circumvents the limitations of using nicotine replacement therapy or bupropion pharmacotherapy in ST users. The overall goal of this line of research is to develop effective pharmacologic treatments for ST users to increase long-term (≥ 6 months) abstinence rates. The central hypothesis of this application is that varenicline is efficacious for the treatment of ST users.

Study identification

NCT ID: NCT00813917
Recruitment status: Completed
Study type: Interventional
Phase: Not applicable
Lead sponsor: Mayo Clinic; Other
Enrollment: 76 participants

Conditions and interventions

Conditions

Nicotine Dependence

Interventions

varenicline Drug
placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2009 (Type not available)
Primary completion: Oct 2010 (Actual)
Completion: Jan 2011 (Actual)
Last update posted: Jul 16, 2012

2009 – 2011

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Nicotine Research Program	Rochester	Minnesota	55905	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00813917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 16, 2012 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00813917 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →